Geographic Atrophy (GA) - Pipeline Insight, 2024

This “Geographic Atrophy - Pipeline Insight, 2024, report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Geographic Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Geographic Atrophy Understanding

Geographic Atrophy: Overview

Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris. It starts typically in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases. Over 8 million people are affected worldwide with GA, approximately 20% of all individuals with AMD. The incidence of GA is expected to rise as the age-burden of developed countries is increasing. Several risk factors have been noted by several studies. The most pronounced risk factor is increasing age and family history of AMD. Smoking history increases the risk of GA significantly. Both active smokers, but also former smokers are at greater risk of developing geographic atrophy.

Geographic Atrophy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Geographic Atrophy pipeline landscape is provided which includes the disease overview and Geographic Atrophy treatment guidelines. The assessment part of the report embraces, in depth Geographic Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Geographic Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Geographic Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Geographic Atrophy.

Geographic Atrophy Emerging Drugs Chapters

This segment of the Geographic Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Geographic Atrophy Emerging Drugs

IONIS-FB-LRx: Ionis Pharmaceuticals IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye.

Zimura: IVERIC bio Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related maculardegeneration.

Geographic Atrophy: Therapeutic Assessment

This segment of the report provides insights about the different Geographic Atrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Geographic Atrophy

There are approx. 23+ key companies which are developing the therapies for Geographic Atrophy. The companies which have their Geographic Atrophy drug candidates in the most advanced stage, i.e. phase III include, IVERIC bio.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Geographic Atrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Geographic Atrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Geographic Atrophy drugs.

Geographic Atrophy Report Insights

• Geographic Atrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Geographic Atrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Geographic Atrophy drugs?
• How many Geographic Atrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Geographic Atrophy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Geographic Atrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Geographic Atrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ionis Pharmaceuticals
• IVERIC bio
• Apellis Pharmaceuticals, Inc.
• NGM Biopharmaceuticals
• Annexon Inc.
• Genentech
• Alexion Astra Zeneca RareDisease
• ONL Therapeutics
• Alkeus Pharmaceuticals
• Regenerative Patch Technologies, LLC
• Astellas Pharma Inc
• Gemini Therapeutics
• Boehringer Ingelheim
• Cell Cure Neurosciences LTD
• Stealth Bio TherapeuticsInc.
• Hemera Biosciences LLC
• Gyroscope Therapeutics Limited
• Eyevensys
• Nanoscope Therapeutics, Inc.
• Catalyst Biosciences
• Novartis

Key Products

• IONIS-FB-LRx
• Zimura
• APL-2
• MCO-020
• CB 2782
• NGM621
• HMR59
• GT 005
• Elamipretide
• ANX007
• RG6312
• OpRegen
• RG6147
• BI 754132
• ALXN2040
• ONL 1204
• ALK-001
• GEM103
• ASP7317
• CPCB-RPE1

This product will be delivered within 1-3 business days.